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ABSTRACT
Introduction: Oral corticosteroids are the cornerstone
of acute asthma management in the emergency
department. Recent evidence has raised doubts about
the efficacy of this treatment in preschool-aged
children with viral-induced wheezing and in smoking
adults. The aims of the study were to: (1) document
the magnitude of response to oral corticosteroids in
children presenting to the emergency department with
moderate or severe asthma; (2) quantify potential
determinants of response to corticosteroids and (3)
explore the role of gene polymorphisms associated
with the responsiveness to corticosteroids.
Methods and analysis: The design is a prospective
cohort study of 1008 children aged 1–17 years
meeting a strict definition of asthma and presenting
with a clinical score of ≥4 on the validated Pediatric
Respiratory Assessment Measure. All children will
receive standardised severity-specific treatment with
prednisone/prednisolone and cointerventions
(salbutamol with/without ipratropium bromide).
Determinants, namely viral aetiology, environmental
tobacco smoke and single nucleotide polymorphism,
will be objectively documented. The primary efficacy
endpoint is the failure of emergency department (ED)
management within 72 h of the ED visit. Secondary
endpoints include other measures of asthma severity
and time to recovery within 7 days of the index visit.
The study has 80% power for detecting a risk
difference of 7.5% associated with each determinant
from a baseline risk of 21%, at an α of 0.05.
Ethics and dissemination: Ethical approval has
been obtained from all participating institutions. An
impaired response to systemic steroids in certain
subgroups will challenge the current standard of
practice and call for the immediate search for better
approaches. A potential host–environment interaction
will broaden our understanding of corticosteroid
responsiveness in children. Documentation of similar
effectiveness of corticosteroids across determinants
will provide the needed reassurance regarding current
treatment recommendations.

Strengths and limitations of this study
▪ The proposed work will be the largest published
cohort study exploring determinants of responsiveness to oral corticosteroids in children treated
according to evidence-based acute asthma
guidelines.
▪ The documentation of exposure using biomarkers to confirm parental reports enhances accuracy and precision of the determinants.
▪ The selection of a primary endpoint, that is, failure
of emergency department (ED) management, the
only clinical outcome that can be documented in all
patients irrespective of age, carries enormous
weight for modifying practice.
▪ A prospective cohort study is subject to potential
biases inherent to this design. Loss to follow-ups
will be quasi non-existent for the main and most
secondary outcomes due to the short duration
of follow-up in the emergency department.
Confounding by indication will be minimised by the
standardised severity-specific therapy.
▪ The inherent variability of admission and assessment of the Paediatric Respiratory Assessment
Measure add noise to the data, which was taken
into account in the sample size.

Results: Results will be disseminated at international
conferences and manuscripts targeted at emergency
physicians, paediatricians, geneticists and
respirologists.
Trial registration number: This study is registered
at Clinicaltrials.gov (NCT02013076).

INTRODUCTION
Asthma is the most common chronic disease
in childhood. It affects over half a million
Canadian children aged 4–11 years.1 Of all
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Treatment of acute asthma
National and international guidelines for the management of acute asthma recommend: (1) inhaled β2-agonists
for all patients; (2) systemic (usually oral) corticosteroids
for those with moderate and severe asthma; and (3)
repeated doses of inhaled β2-agonists and anticholinergics
for severe cases.6 7 9 10 The latter two recommendations
independently reduce admission rates by 25% in studies of
predominantly school-aged children.11 12 Several features
must be noted. First, recommendations are severityspeciﬁc; patients with mild asthma do not appear to
beneﬁt from oral corticosteroids.11 13 Second, the concept
of the ‘golden ﬁrst hour of treatment’ supports early and
aggressive asthma management, as the risk of admission is
reduced only when oral corticosteroids are administered
3–4 h prior to the decision to admit. Third, of all treatments administered in the ED, oral corticosteroids are by
far the most effective for preventing admission.14 Fourth,
there is no equally effective substitute for oral corticosteroids; promising contenders such as high-dose inhaled steroids,15 16 intravenous antileukotrienes17 or magnesium
sulfate18 have been shown to be inferior to oral corticosteroids and are used as an add-on therapy. Fifth, systemic corticosteroids are inexpensive generic drugs. Short
treatment with oral corticosteroids is generally devoid of
signiﬁcant side effects,19 though rare cases of fatal or disseminated varicella have been reported.20 Sixth, while
recommendations are relatively similar in young children,
older children and adults, the evidence for the former is
weaker due to the under-representation of preschool-aged
children in relevant trials.11 12 While oral corticosteroids
are the cornerstone of management of acute, moderate or
severe asthma,6 several reports have recently shaken the
belief that they are equally effective for all patients with
asthma, showing that children with viral-induced wheezing21 and smoking adults22 are corticosteroid-resistant.
Indeed, in a large placebo-controlled randomised controlled trial of 700 children aged 10–60 months with
mild-to-moderate viral-induced wheezing, oral corticosteroid was not superior to placebo for reducing the length of
stay in hospital or improving the Pediatric Respiratory
Assessment Measure (PRAM) clinical score, despite
adequate study power.21 Critics have suggested that: (1) in
most children, the disease may not have been asthma
(documented in only 16% of patients) but rather the
North American deﬁnition of bronchiolitis; (2) some
patients (with mild asthma) may not have needed
2

corticosteroids23; (3) the prolonged stay in hospital did
not seem to be supported by severity24 and (4) the dose of
1 (instead of 2) mg/kg may have been insufﬁcient. Yet,
this study elicited major discomfort regarding acute
asthma management in young children.24 In another
adequately powered landmark trial, a 2-week treatment
with prednisone showed a marked blunting of response in
adult smokers, with an improvement in forced expiratory
volume in 1 s (FEV1) of 237 mL (95% CI 43 to 431) in
never-smokers compared to no change or 47 (−148 to
243) mL in current smokers.22 The question remains as to
whether smoking adolescents and children with environmental tobacco smoke (ETS) respond as well as those not
exposed. None of these aforementioned ﬁndings have
been replicated, thus prompting us to review the potential
determinants of responsiveness.
Potential determinants of response
Disease diagnosis
Children with bronchiolitis do not respond to oral corticosteroids, although a recent trial has demonstrated a signiﬁcant response only in association with nebulised
epinephrine.25–27 It is thus critical to distinguish asthma
from bronchiolitis in young children.28 Bronchiolitis is
clinically deﬁned in North America as the ﬁrst wheezing
illness in a child ≤12 months, with respiratory syncytial
virus (RSV) as the most frequent pathogen. Asthma,
deﬁned as airway obstruction (cough, dyspnoea and
wheezing) with hyper-reactivity and reversibility with bronchodilator or corticosteroids, begins early in life.29 30
While children and adults meeting these criteria can be
diagnosed at the ﬁrst episode, generally three wheezing
episodes are required for children ≤12 months to reduce
the risk of misclassiﬁcation with bronchiolitis.8 31
Heterogeneous groups of children with bronchiolitis and
asthma may explain the poor response to oral corticosteroids in studies including infants and toddlers.21 24 Thus,
an operational deﬁnition of asthma, clinically applicable
to children aged 1–17 years, is needed to reasonably
exclude bronchiolitis.
Upper respiratory tract infections
Upper respiratory tract infections (URTIs), usually viral
in origin, are the most frequent (60–80%) triggers of
asthma exacerbation in children.32–34 RSV, parainﬂuenza
virus and rhinovirus are frequently implicated in children under 2 years of age, while picornavirus, coronavirus and inﬂuenza are usually associated with asthma in
older children.35–38 The incidence of viral-induced
asthma peaks in September continues throughout the
fall and winter.32 In adults with acute asthma, viral infection is associated with longer hospital admission39 and
increased sputum neutrophils, suggesting a predominantly neutrophilic airway inﬂammation.39 In a study of
children aged 3–36 months, those infected with rhinovirus showed fewer relapses when treated with oral prednisone compared to placebo, suggesting that rhinovirus
did not impair responsiveness to steroids.40 In another
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respiratory illnesses, asthma is one of the most frequent
paediatric diagnoses requiring hospital admission.1 The
burden of illness is much higher in preschool-aged children, who account for over 50% of emergency department (ED) visits1–4 and who have three times the
hospital admission rate of older children and adolescents.5 The difﬁculty in measuring asthma severity in
young children has resulted in a dearth of comparative
therapeutic evidence between preschoolers and older
children.6–9

Open Access

Exposure to tobacco smoke
In addition to the aforementioned trial demonstrating
no response to oral corticosteroids in asthmatic adult
smokers,22 a blunted response to inhaled corticosteroids
was also documented in adult smokers in two randomised controlled trials.42 43 While the mechanism
behind the lack of response is not known, one can certainly point to smoking’s direct toxicity, proinﬂammatory
action or interference with the transcription of genes
associated with corticosteroid response.22 Indeed,
smoking has frequently been associated with airway neutrophilia.44 In paediatrics, exposure to tobacco smoke
has been associated with a higher incidence of URTIs
and prevalence of asthma, and a greater severity of
exacerbations.45 However, the impact on the therapeutic
response has not been documented in children, as
asthma trials have not examined or failed to report subgroup analyses on ETS exposure or active smoking.
Heavier ETS exposure in preschoolers who spend more
time at home than school-aged children46 47 may
explain a poorer response in young children. Objective
documentation of smoking would also be important if
possible, even before high school where many already
smoke.48 Of particular concern is whether a blunted
response to oral corticosteroids would be found in children exposed to tobacco smoke and adolescents with a
short history of active smoking. With 25% of asthmatic
children exposed to ETS and 25% of teenagers actively
smoking,49–51 such an assessment appears critical.
Several reports highlight the need for objective measurement of nicotine exposure, because of parental underreporting of their child’s exposure to ETS.46 52 Cotinine, a
nicotine metabolite with a half-life of 20 h, is a widely
accepted indicator of recent tobacco use and exposure.53
Serum cotinine requires blood sampling, a major deterrent for study participation in paediatrics.47 53 Good correlations exist between serum and either salivary (r=0.71) or
urine (r=0.69) cotinine measures.53 With a 1:10 ratio of
cotinine level between saliva and urine,54 passive exposure
may lead to saliva levels of 5–10 ng/mL55 56 and urine
levels of 10–100 ng/mL.45 However, as urine sampling in
young children may not occur for several hours and is
more complex to obtain in children not yet toilet-trained,
saliva cotinine measured by the quantitative enzyme
immunoassay kit is a well-validated, non-invasive solution

that offers required precision with minimal volume and a
detectable level of 0.05 ng/mL.56 57
Other determinants
A number of other factors could possibly modulate the
responsiveness to oral corticosteroids including, among
others, gender,1 race,58 59 perceived asthma phenotype
(derived from age, common asthma triggers and interim
symptoms),31 60 61 inhaled corticosteroids,2 73 62 allergens,
the alleged trigger,63 and other environmental triggers, all
of which can be documented clinically by questionnaire.
Mechanistic pathways
Two promising mechanistic pathways may explain the
variations in the magnitude of response observed in clinical effectiveness, namely (1) gene polymorphisms that
may reveal potential gene–environment interactions and
(2) the type of airway inﬂammation.
Gene polymorphisms
There is increasing evidence that inherited genes are not
a deterministic genotype, but rather a genotype that
encodes a potential range of phenotypes that will develop
in response to a variety of environments.64 Consequently, a
minor polymorphism between individuals in genes that
modulate response to corticosteroids may predispose
some people to environmentally induced problems, such
as smoke-induced or viral-induced asthma.65 66 Two major
groups of genes are of interest: (1) those affecting susceptibility to asthma and (2) those directly interfering with
response to corticosteroids by coding for major components of the pathway involved in corticosteroid action
(table 1). In the ﬁrst group, we selected eight polymorphisms in seven genes that can be divided into those coding
for xenobiotic metabolising enzymes and those coding for
mediators of inﬂammation and immunity, speciﬁcally the
ones demonstrated to affect lung function, disease severity
and interaction with exposure to ETS.67 68 We selected
polymorphisms affecting gene function, top-ranking
single-nucleotide polymorphisms (SNPs) in a number of
associated studies. Transforming growth factor β 1 polymorphisms were found to correlate with disease severity69;
CC16 polymorphisms play a role in the development and
persistence of the asthma phenotype in childhood70;
CD14 polymorphisms have been linked to pathogenesis of
asthma and lung function in smokers.71 The ORMDL3
gene confers susceptibility to early-onset asthma, particularly through interaction with early life exposure to
ETS67 72; GSTM1 and GSTP1 are involved in the metabolism of polycyclic aromatic hydrocarbon derivatives and
reactive oxygen species73 74; GSTM1 null and GSTP1 genotypes have been associated with an increased risk of
asthma75 and rapid decline of lung function among
smokers.76 The ADRB2 receptor gene was found to contribute to the occurrence of wheeze among children who
were exposed to tobacco smoke in utero and in early childhood77 and was related to β2-agonist response.68 78 Among
genes affecting the corticosteroid and inﬂammatory
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placebo-controlled trial of 283 young children with
wheezing, prednisolone did not signiﬁcantly decrease
the overall time to discharge; however, it reduced by half
the length of stay in children infected with picornavirus
and by fourfold that of children with enterovirus, suggesting that response may be organism dependent.41
Clearly, oral corticosteroids may not be as effective in
patients with viral infections as in those without, perhaps
due to neutrophilic airway inﬂammation, a condition
associated with poor response to corticosteroids.
Moreover, response may be organism speciﬁc, a hypothesis that requires careful documentation of aetiology.

Open Access

Gene
TGF-β11

Transforming growth factor β

CD141
CC161
ADRB21
GSTM1*
GSTP1*
ORMDL3*
CRHR1†
TBX21†

Monocyte differentiation antigen CD14
Clara cell 16 kDa secretory protein
β-2-adrenergic receptor
Glutathione S transferase M1
Glutathione S transferase P1
Orm1-like protein 3
Corticotropin-releasing hormone receptor 1
Tbox 21

FCER2†
GLCCI1†
SERPINE1†
STIP1†
STIP1†

Fc fragment of IgE, low affinity II, receptor for (CD23)
Glucocorticoid-induced transcript 1
Plasminogen activator inhibitor-1,
Stress-induced phosphoprotein
Stress-induced phosphoprotein

Location

Position/SNP annotation

Promoter
Coding
Promoter
50 UTR
Coding
Gene deletion
Coding
Intronic
Intronic
Coding
Promoter

-C-509T rs1800469
T869C rs1982073
C-159T rs2569190
A38G rs3741240
Arg16Gly rs1042713
GSTM1 null genotype
Ile105Val rs1695
A/C rs4795405
A/G rs242941
H33Q rs2240017
T-1514C rs17250932
G-999A rs11650451
T-1993C rs4794067
T2206C rs28364072
C/T rs37972
−675 4G/5G rs1799889
G/T rs4980524
rs2236647

Intronic
50 UTR
Promoter

*Relevance for asthma phenotype.
†Relevance for corticosteroid response.
SNP, single-nucleotide polymorphism.

pathways, we selected genes (CHRH1, TBX21, FCER2,
GLCC1, STIP1 and SERPINE1) that were shown to correlate with response to corticosteroids in patients with
asthma; the ﬁnding for some of them was replicated in
several cohorts.79–84 All selected polymorphisms with the
gene name, position and corresponding reference are
summarised in table 1. Genotyping is essential to link the
observed corticosteroid response to genotype and to evaluate the potential host–environment interaction.
Airway inflammation
Induced sputum is a valid, reproducible and non-invasive
method of assessing the magnitude and pattern of airway
inﬂammation in adults and children.85 Sputum cell counts
and differentials (ie, eosinophils and neutrophils) determine the inﬂammatory phenotype; analysis of supernatants
for eosinophil cationic protein (ECP), interleukin-8 (IL-8)
and myeloperoxidase provides measures of cellular activation. Sputum eosinophils and ECP increase with exposure
to allergens and decrease with corticosteroid treatment.86
A higher proportion of neutrophils is associated with
smoking22 44 87 and with viral infection.39 88 The
non-eosinophilic inﬂammatory phenotype in adults has
been associated with poor response to corticosteroids.89 90
Markers of this phenotype include an increased proportion
of neutrophils, IL-8 and myeloperoxidase, all of which are
easily quantiﬁable.91 92 Contrary to adult ﬁndings and criteria, three distinct inﬂammatory cell patterns have been
reported during paediatric exacerbations: non-eosinophilic
(<2.5% eosinophils) in 22%, eosinophilic (≥2.5% eosinophils) in 43% and combined eosinophilic/neutrophilic
(≥2.5% eosinophils and >54% neutrophils) in 35%, with
paucigranular inﬂammation not described in acute
4

paediatric asthma.62 Combined eosinophilic/neutrophilic
exacerbations show more mast cells and higher sputum
ECP levels than eosinophilic exacerbations. There is
increasing evidence that eosinophilic asthma is more
responsive to corticosteroids than non-eosinophilic asthma;
a promising mechanistic pathway to explore.93 94
Expired nitric oxide (eNO) is increasingly recognised as
a non-invasive marker of airway inﬂammation, particularly
in atopic asthma,95 96 and correlates strongly with the percentage of airway eosinophils (r=0.78) and ECP (r=0.53)
in children with asthma.97 Although the understanding
about the link between NO and airway inﬂammation
remains incomplete, airway epithelial cells activated by
inﬂammatory cytokines produce an increased amount of
eNO due to the expression of inducible NO synthase.98
eNO is elevated in untreated asthma99 and improves with
asthma therapy.100 101 Of interest, eNO correlates with
other markers of eosinophilic inﬂammation, including
sputum eosinophils.102 103 Thus, eNO appears to reﬂect
the magnitude of eosinophilic airway inﬂammatory and
may serve as a promising biomarker of eosinophilic inﬂammation in children too young or unable to cooperate with
induced sputum sampling.104 As it can be measured in
preschool-aged using an ofﬂine technique105 106 and in
older children using commercially available instruments,107 108 it could serve as a biomarker of subsequent
response to corticosteroids if indeed the type of airway
inﬂammation modulates response.
Selection of outcomes
Healthcare service utilisation
The need for hospital admission is a powerful marker of
therapy failure, likely to alter physicians’ practice and
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Table 1 Summary of the polymorphisms in subset of candidate genes of relevance for asthma phenotype and
corticosteroids response
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Indicators of airway dysfunction
Accurate and objective assessment of the severity of airway
obstruction is clearly the biggest challenge in acute paediatric asthma research. Standard lung function tests, such
as spirometry, require a forced expiratory manoeuvre that
is extremely difﬁcult and unreliable for preschool-aged
children because of poor coordination; it is not obtainable
in 35–50% of acutely ill school-aged children because of
illness severity and/or poor familiarity with technique.110–
112
About three quarters of asthmatic children cannot
perform standard lung function tests in the ED setting.113
In contrast, respiratory resistance (Rrs) by forced oscillation is an effort-independent measure that can be
obtained in untrained, acutely ill children aged ≥3 years110
We and others have demonstrated the reproducibility and
sensitivity to change Rrs114 and established reference
values for Canadian children.115 116 Thus, the measure of
Rrs can serve as a precise and reliable index of severity and
response in acutely ill children, although still missing very
young or uncooperative preschoolers and as such cannot
serve as the main outcome.
Clinical scores appear to be a reasonable alternative to
lung function testing as they can be used in children of all
ages. Although many clinical scores have been designed,
only two have been validated for use in both
preschool-aged and school-aged children.112 117 The
PRAM is the only score developed and validated against
a concurrent measure of lung function in children aged
3–6 years,117 and subsequently validated in children aged
1–17 years.23 It is a discriminative and responsive tool, with
a change in scores ≥3 indicating clinical importance.23 117
The inter-rater reliability is consistently above 70%.23 The
12-point PRAM, rating ﬁve weighted items (oxygen saturation, suprasternal retractions, scalene muscle contraction,
air entry and wheezing), has been used in landmark clinical trials.21 It can be used to assess severity at baseline
(mild: PRAM 0–3; moderate: PRAM 4–7; severe: PRAM
8–12), improvement with treatment depicted as the area
under the curve, need for admission (PRAM ≥4, 4 h after

the oral corticosteroids) and time until ready for discharge
(delay until PRAM <4).23
Indicators of recovery following discharge
Among children discharged home, the time to complete
recovery will vary widely between individuals. Although
symptom scores are frequently used in clinical trials, only
four have been speciﬁcally developed for use in children.69 70 71 The Asthma ﬂare-up diary for young children
(formerly the Pediatric Asthma Diary) is the only one validated to detect day-to-day change in the functional status
of preschool-aged children following an acute care visit118;
it is highly sensitive to detect group differences in intensity
and duration of symptoms in randomised controlled trials;
however, its performance in school-aged children has not
been explored.119 Another diary has been validated for
detecting change in school-aged children but not in the
context of acutely ill children.120 Use of β2-agonists is an
additional marker for the duration and intensity of symptoms, as greater use of rescue relievers is expected to
occur in children with more symptoms.119 Finally, the
impact of the disease on the quality of life of the patient or
the caregivers is a recognised, sensitive and unique marker
of the burden of disease on the patient or family.121
Several well-validated asthma-speciﬁc quality of life instruments are available for adults122 and school-aged children
with stable asthma.123 To our knowledge, only one instrument, entitled ‘Effects of a child’s asthma ﬂare-up on
parents’, is available for measuring the burden of disease
on parents of preschool-aged children following an
asthma exacerbation; we have developed the instrument
using Kirshner and Guyatt’s124 approach for developing
health instruments, validated it in a randomised controlled
trial119 and received two copyrights (French version:
#1019528 English version: #1019529 (manuscript in
preparation).
Hypothesis
In children presenting with moderate or severe asthma
to the ED:
1. Preschool age, speciﬁc viral triggers and exposure to
tobacco smoke are independently associated with
increased risk of failure of ED management (risk difference (RD) ≥7.5%).
2. Speciﬁc genetic polymorphisms alone or in association with environmental factors are associated with
higher risk of admission.
3. An eosinophilic pattern of airway inﬂammation (ie,
percentage of eosinophils on induced sputum and/
or baseline eNO) is associated with greater clinical
improvement as measured by the PRAM area under
the curve over 4 h (nested cohort).
OBJECTIVES
The main objective was to identify and quantify clinically
available factors (eg, age, speciﬁc viral trigger and ETS)
associated with failure of ED management and other
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inﬂuence decision makers as hospital costs alone account
for 43% of total asthma costs.109 Although subject to practice variation, a physician’s decision to admit is usually
based on an unsatisfactory response to bronchodilators
and systemic corticosteroids in the ED, indicating severe
asthma or poor response to corticosteroids.22 Admission
may be affected by other reasons such as parental anxiety,
distance or fatigue and, of course, availability of ED and
hospital beds.50 Adding a cut-off length of ED stay, above
which a patient is considered admitted, limits the impact
of external factors (bed availabilities) which may vary
widely within and between institutions. Moreover, incorporating return visits resulting in admission provides an
additional measure of failure of ED treatment by adding a
measure of the decision appropriateness. Time to meet
severity criteria for discharge (PRAM <4) and length of
active treatment are two additional measures of interest
that are less inﬂuenced by factors other than severity.

Open Access

Secondary objectives
1. Examine the association between speciﬁc genetic
polymorphisms (including potential host–environment interactions) and markers of response.
2. Determine whether the type of airway inﬂammation
(ie, eosinophilic and eNO) is associated with the
magnitude of response to corticosteroids and which
host or episode characteristics are associated with a
speciﬁc type of inﬂammation.
METHODS
Design
The study design is a multicentre prospective cohort
study with a standard intervention involving 1008 children aged 1–17 years of age presenting with acute
asthma to one of the ﬁve participating Canadian paediatric EDs. The study includes a nested cohort study of
children who presented at selected centres and who
could cooperate with eNO measurements (about 200)
or induced sputum (about 60 children aged ≥8 years) to
explore the pattern of airway inﬂammation.
Subjects
Participants will be eligible if they: (1) are aged 1–17
years; (2) have asthma, deﬁned as: (i) prior diagnosis of
asthma made by a physician; (ii) prior documented
episode of acute cough, wheezing and/or dyspnoea with
signiﬁcant response to inhaled β2-agonists or to oral corticosteroids; (iii) in a child aged <2 years, three or more
episodes of cough, wheezing and/or dyspnoea, including the index visit or (iv) previous lung function tests
showing signiﬁcant reversibility postbronchodilation
(≥12% FEV1 or ≥25% Rrs at 4–8 Hz)117 or a positive
provocation test (PC20 ≤8 mg/mL or provocation dose
(to increase Rrs by 50% or more (PD50) ≤8 mg/mL), in
keeping with the American Thoracic Society and
European Respiratory Society criteria125 126; (3) present
with an acute episode of cough, wheezing and/or dyspnoea; (4) have moderate-to-severe airway obstruction,
deﬁned as a PRAM score >3 at baseline; (5) have a good
understanding of English or French and (6) are accompanied by parents or legal guardians.
Patients will be excluded if they present: (1) with
another chronic respiratory condition (such as bronchopulmonary dysplasia or cystic ﬁbrosis); (2) with a reasonable suspicion of bronchiolitis or foreign body
aspiration; (3) a history of hypersensitivity to salbutamol,
ipratropium bromide or oral prednisolone; (4) a relative
or absolute contraindication to receiving oral corticosteroids such as recent exposure to varicella or live vaccine
in a susceptible child or (5) with conﬁrmed or suspected pregnancy status. As some inclusion and exclusion criteria may become evident during or after the ED
6

stay (ie, pneumonia), a central adjudicating committee
comprising a paediatrician/ED physician and respirologist will review the eligibility criteria of children who,
after enrolment, appear to be ineligible due to the
failure to meet one or more inclusion or exclusion criteria and who did not receive or tolerate oral corticosteroids as recommended in the protocol. The main trigger
for identifying these children will be the ED physician’s
low degree of conﬁdence that this child had asthma, suspicion that he/she may have bronchiolitis and the suspicion that he/she did not retain the oral corticosteroids.
In this case, the relevant case report forms, relevant
anonymised laboratory testing (ie, imaging, microbiology, virology and haematology) and relevant anonymised
medical chart sections will be reviewed by the adjudicating committee. The adjudicating committee will be
central, although we are not ruling out the possibility of
creating local committees at each site, depending on the
volume of cases to review. In such a case, the site would
be added as a covariate in the analysis. Disagreement
will be resolved by consensus or the assistance of a third
observer. The proportion of excluded children, assumed
to be around 10%, will be monitored and reported.
Standardised acute treatment protocol
As per the evidence-based paediatric national127 and
international guidelines,9 children will be treated
according to a standardised severity-speciﬁc protocol
(table 1). All children will receive 2 mg/kg (maximum
50 mg) of oral prednisolone (or prednisone) within
60 min of triage, along with inhaled salbutamol with or
without inhaled ipratropium bromide as per severity
strata. Discharge medications will include a 5-day course
of oral prednisolone at a dose of 1 mg/kg/day and
inhaled β2-agonists as needed. Cointerventions, such as
add-on therapy with magnesium sulfate in the ED or
inhaled corticosteroids at discharge, will be permitted
and recorded. Comorbidities (eg, pneumonia, sinusitis,
allergic rhinitis, etc) and adverse health events will be
documented.
Measurements of effectiveness
The primary outcome, serving as a proxy for suboptimal
response, is the failure of ED management deﬁned as a
hospital admission for asthma (as primary or secondary
diagnosis if the primary diagnosis is a complication or
comorbidity of asthma) or ED stay for asthma (with active
treatment) of ≥8 h after intake of oral corticosteroids or a
return visit within 72 hours meeting either of the two
previous criteria (admission or length of active treatment
≥8 hours). The 8 h time constraint was included to
account for extraneous factors affecting admissions, such as
variation in bed availabilities while the child remains under
treatment on site.
Secondary measures of effectiveness in the ED include:
(1) meeting the severity criteria for admission, that is, a
PRAM score ≥4 within 4 h of corticosteroid administration (to account for other reasons for hospital
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markers of clinical response to oral corticosteroids in
preschool-aged and school-aged children presenting to
the ED with moderate or severe asthma.
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have a nasopharyngeal aspirate or nasopharyngeal swab
(Flocked swab, Copan Diagnostics, California, USA) performed. The aspirate or swab will be put in 3 mL of viral
transport media (UTM, Copan Diagnostics, California,
USA) and split in half on site. The ﬁrst half will be
tested using routine methods in each site if clinically
required and the other half will be frozen at −80°C for
molecular diagnosis. The frozen samples will be processed using the validated automated microarray detection,129 which tests for 23 common respiratory viruses,
including the novel inﬂuenza A/H1N1/Mexico.
Passive exposure to tobacco smoke will be quantiﬁed by a
questionnaire speciﬁcally enquiring about current smoking
and the amount of smoking by household members,
cumulative smoke exposure in pack-years since birth and
in utero exposure, using validated questions.51 130 Active
smoking will be assessed by asking school-aged children
aged 10 years and older, while alone, if they smoked in the
past 7 days, using standardised questions used by the
Quebec Institute of Statistics.131 A quantitative cotinine by
quantitative enzyme immunoassay kit (Salimetrics,
Pennsylvania, USA) will be performed on saliva sampled
using three Sorbettes (a wand with a small sponge) according to a previously described protocol.56 57
Several other factors will be considered, including an
assumed trigger. In the absence of valid biomarkers of
causal relationship to the exacerbation, the alleged
trigger (allergic or other) based on the parental report,
physician perception, prior documented sensitisation
(skin tests or speciﬁc IgE), pollen, particles, ozone (and
other) levels in the child’s living area will serve to infer a
trigger.

Potential determinants
Sociodemographic variables
Basic characteristics will be documented, including age,
gender, neighbourhood ﬁnancial income derived from
six-digit postal codes from both parents (if separated),
medical insurance ( private or public) and ethnicity as
reported by the parents and classiﬁed as per the latest
Canadian Census questionnaire.
Phenotype and morbidity
Children’s asthma phenotype will be documented as per
the latest international recommendations (ie, viral
induced, exercise induced, allergen induced and multiple trigger).31 Prior morbidity (admissions, ED visits
and rescue oral corticosteroids), asthma control using
the Asthma Quiz for Kidz,128 reported use of daily controller medications, environmental factors (eg, dust,
animals and pollen) and perceived trigger of the exacerbation will be documented. Prior allergy test results,
serum IgE (speciﬁc) will be obtained (with permission)
as well as pollen counts in the area.

Mechanistic pathway
Genetic profile
Patients’ DNA will be extracted from saliva expectoration
or collected on Sorbettes designed for young children,
with only a small amount (1–2 mL) needed for DNA
analysis. After ampliﬁcation by PCR, key polymorphisms132 133 will be determined by high throughput genotyping technology (Sequenom platform) for custom SNP
panels.
eNO will be measured on a chemiluminescence analyser (the Niox Flex or the portable Niox Mino from
Aerocrine, New Providence, New Jersey, USA or Sievers
from GE Analytic Instrument, Boulder, Colorado, USA),
using standardised techniques98 in cooperative children
aged ≥4 years; the measurements will be taken before
corticosteroids and at 4 h or disposition, whichever
occurs ﬁrst. In children unable to cooperate with these
techniques, the eNO will also be measured, using the
single breath manoeuvre, in an inert balloon (ofﬂine
technique) and then analysed on the chemiluminescence analyser.105 106

Viral trigger
Acknowledging viruses as the major trigger, all children
will be tested for respiratory viruses. All children will

Induced sputum
After the initial salbutamol inhalation, children aged
≥7 years will be asked to expectorate spontaneously or, if
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admission); (2) the PRAM proﬁle in the ED, measured
hourly from baseline and every hour until disposition (or
until 4 h after intake of oral corticosteroids, whichever
occurs ﬁrst) and reported as the area under the curve;
(3) time to PRAM ≤3, that is, meeting the criteria for discharge; (4) length of active treatment deﬁned as duration
between the ﬁrst and last salbutamol inhalation. Finally,
to allow more objective and precise quantiﬁcation of
response in a nested cohort (CHU Ste-Justine), (5)
change in Rrs between baseline and disposition will be
documented on the MasterScreen Impulse Oscillometry
(Cardinal Health Canada, Montreal, Canada) using previously described standardised techniques110 114 126 in
cooperative children aged ≥3 years, (6) change in eNO
between baseline and disposition will be documented on
a chemiluminescence NO analyser in cooperative children aged ≥4 years and (7) hospital admission for
asthma (as primary or secondary diagnosis) within 72 h
or an active ED stay of ≥8 h after intake of oral
corticosteroids.
Secondary measures of resolution of exacerbation measured after discharge will be documented over the next
10 days in all patients: (8) unscheduled visits for asthma
as reported by parents and conﬁrmed by medical charts;
(9) cumulative symptom score and duration of symptoms
measured daily on the validated Asthma ﬂare-up diary for
young children (formerly named the Paediatric Asthma
Diary)118; (10) parent quality of life measured on the
‘Effect of a child’s asthma ﬂare-up on parents’ and (11)
the cumulative number of puffs and duration of use of
rescue β2-agonists as recorded on the Asthma ﬂare-up
diary for young children.
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Procedures
Within each institution, potentially eligible patients aged
1–17 years will be identiﬁed on arrival in the ED. As per
standard practice in each of the participating hospitals,
all children will be triaged and scored on the PRAM at
or shortly after triage. The ﬁrst inhalation of salbutamol
and, for severe exacerbations, ipratropium bromide will
be administered (ﬁgure 1). Using a two-step informed
consent, parents will ﬁrst give their authorisation for
their child to receive standardised severity-speciﬁc treatment and, at the CHU Ste-Justine, lung function testing
and induced sputum in cooperative children. Parents
will then receive a detailed explanation of the study and
be offered study participation. Participants will receive
the treatment and measures detailed in ﬁgure 1, with
key measurements obtained prior to corticosteroids.

Statistical analyses
Standard summary statistics (N, mean, SD, median,
minimum and maximum for continuous variables; N and
proportion for categorical variables) will be computed
for all variables for the whole cohort and by institutions.
Two-sided 95% CIs will be presented as necessary. For the
primary endpoint, failure of ED management and other
dichotomous outcomes, bivariate and multivariate logistic regression models will be used to examine the association with each potential determinant and to adjust for
site, baseline severity and other relevant covariates of
interest. ORs will be estimated and presented with twosided 95% CIs. Continuous outcomes, such as the area
under the curve for repeated PRAM measures, daily
Asthma ﬂare-up diary for young children or intensity of
both β2-agonist use and symptom scores after discharge,
will be analysed using linear regression models.
Transformation of variables will be performed if necessary to account for non-normality of the residuals.
With regard to pharmacogenomics, we will compare
the frequency of SNPs between patients with versus
8

without failure of ED management using Fisher’s exact
tests and examine the strength of the association with
failure of ED management with bivariate and multivariate
logistic regression. Genotypes will be considered as variables with two (dominant or recessive models) or three
(additive model) categories. The choice of the model is
determined by the functionality of selected polymorphisms and previous reports. Bonferroni correction will be
used to adjust for multiple testing ( p=0.005, adjusted for
10 independent genes investigated). Host–environment
interaction will be examined by adding other covariates
of interest to the genotype model. For example, to investigate genetic heterogeneity according to early-life exposure to ETS, we will introduce markers of tobacco smoke
exposure status.
With regard to examining eosinophilic inﬂammation
as a marker of responsiveness, the area of the curve of
serial PRAM measurements and time to PRAM <4 will
serve as outcomes. Linear regression will be used to
examine the bivariate and multivariate relationships
between sputum eosinophils counts, patterns of inﬂammation (eosinophilic, non-eosinophilic and mixed) and
baseline eNO with the PRAM proﬁle (area under the
curve); the standard survival curve will explore the difference in time to meet criteria for discharge, censored
at 4 h.137 All models will be checked using appropriate
regression diagnostics. Results will be reported as signiﬁcant when p<0.05.
Sample size
Sample size was estimated in two steps using hospital
admission as the dependent variable in a multivariate
logistic regression model. Pilot data were extracted from
two large recent chart audits14 138 totalling 1628 children presenting with acute asthma to the ED (in which
age, gender, baseline PRAM, timing of oral corticosteroid intake and admission were documented) and two
recently completed trials119 139 totalling 518 children, in
whom tobacco exposure was also ascertained by questionnaire; we then focused only on children meeting
our current eligibility criteria (age, baseline PRAM and
corticosteroids within an hour of arrival). Based on the
literature, we assumed the prevalence of viral pathogen
varied between 60% and 80%.140 141 The baseline risk of
admission was 41%; after recruitment of the initial 320
patients, the observed overall risk of admission was substantially lower at 16%, which substantially reduced the
effective sample size from 1200 to 800. First, using the
Wald test (based on the prevalence of factors and the
risk of admission in unexposed children), we calculated
the sample size required to detect an RD of admission
of 7.5%, taking each determinant in turn as the independent variable in a bivariate logistic regression; we
used 95% CIs for each estimate obtained from pilot data
to examine the impact on power.142 Then, using the
method proposed by Hsieh et al,143 we calculated the
inﬂation factor to adjust the total sample size, based on
the observed correlation between key determinants
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unsuccessful, receive a nebulisation of 0.9% saline solution over 7–10 min at 5 L/min with oxygen. With this
technique, a 70% success rate was obtained among
acutely ill school-aged asthmatic children.134–136
Throughout the induction, lung function tests using Rrs
will be documented to ensure that the coughing effort
does not induce bronchospasm.134 Sputum will be processed according to standard techniques within 8 h.
Brieﬂy, sputum will be separated from the saliva and dispersed using dithiothreitol. The dispersed suspension is
then centrifuged and ﬁltered; cytospin slides will be prepared on site by a trained medical technologist, and the
supernatant frozen at −70°C for subsequent quantiﬁcation of inﬂammatory mediators. Differential cell counts
and inﬂammatory mediators will each be analysed by an
independent laboratory, blinded to exposure and
outcome.
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(age, gender and tobacco exposure, and baseline severity). As the observed correlation between determinants
and severity and any pair of determinants was negligible
(β coefﬁcients <0.03), there was no need to inﬂate the
sample size. At an α of 0.05, a sample of 800 children
had 80% power to detect an RD of admission of ≥7.5%
for all key determinants. We targeted the RD of 7.5%,
because it was considered in a survey of researchers of
the Pediatric Emergency Research in Canada (PERC)
network as a clinically meaningful effect size that would
support a practice change. After documenting a 1% loss
after enrolment (from 10% originally estimated) and
20% missing key samples (viral or cotinine), our target
recruitment sample is 1008 to obtain an effective sample
of 800 children. Acknowledging that the majority of
selected polymorphisms have a minor allele frequency
of at least 30% and using an α of 0.005 (with a
Bonferroni correction for 14 polymorphisms), 1008 children will provide 80% power to detect an OR of 1.5
between each polymorphism and admission. Finally, of
the expected 400 children recruited at the University
Health Centre Sainte-Justine, we estimated that 200 children would cooperate with eNO measurements and 60
with induced sputum. These sample sizes should be
adequate to detect a correlation coefﬁcient as low as
0.2–0.35, respectively, with the area under the curve of
the PRAM score during the ED with 80% power and a
two-sided 0.05 α.

ETHICS AND DISSEMINATION
This study poses little risk to participants, as all children
will receive state-of-the-art asthma management with oral
corticosteroids, an approach associated with minimal side
effects.19 144 145 Children will be assessed for potential
contraindication to corticosteroids prior to enrolment.
Using a two-step informed consent, parents will ﬁrst give
their authorisation for their child to receive the severityspeciﬁc asthma protocol and, at speciﬁc centres, lung
function testing and induced sputum in cooperative children; then they will consent to the full study including
sampling for cotinine, DNA and viruses. All parents will
sign an informed consent form authorising the DNA analysis for the speciﬁed research purpose as well as future
analyses (including biobanking of DNA in anonymised
fashion), provided these are approved by the institutional
ethics boards. Assent will be obtained from children aged
≥7 years. The collection of saliva by expectoration or
sponge is painless and well tolerated by children.
Nasopharyngeal aspiration or swab for viral diagnosis is a
commonly used procedure in the ED setting; it is rapid
and associated with little discomfort. The performance of
Rrs and eNO is non-invasive and devoid of serious side
effects. Sputum induction with 0.9% saline and salbutamol pretreatment is a safe procedure in the acute care
setting.134–136 Data safety is maximised through:
restricted physical access to computers and electronically
protected servers (ﬁrewall, restricted password-protected
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Figure 1 The treatment protocol is stratified on the severity of asthma exacerbation, that is, moderate or severe, as measured
by the validated Pediatric Respiratory Assessment Measure (PRAM). Categories of medications are listed in the three columns.
The three horizontal panels describe therapy administered in the first 60 minutes (top panel); after the initial 60 minutes (middle
panel); and on discharge (bottom panel).
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